These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 34791636

  • 1. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
    Kang SK, Bae HJ, Kwon WS, Kim TS, Kim KH, Park S, Yu SY, Hwang J, Park J, Chung HC, Rha SY.
    Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
    [Abstract] [Full Text] [Related]

  • 2. A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction.
    Damaneh MS, Hu JP, Huan XJ, Song SS, Tian CQ, Chen DQ, Meng T, Chen YL, Shen JK, Xiong B, Miao ZH, Wang YQ.
    Invest New Drugs; 2020 Jun; 38(3):700-713. PubMed ID: 31267379
    [Abstract] [Full Text] [Related]

  • 3. Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells.
    Kang SK, Bae HJ, Kwon WS, Che J, Kim TS, Chung HC, Rha SY.
    Genomics Inform; 2020 Dec; 18(4):e37. PubMed ID: 33412753
    [Abstract] [Full Text] [Related]

  • 4. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
    Kong B, Zhu Z, Li H, Hong Q, Wang C, Ma Y, Zheng W, Jiang F, Zhang Z, Ran T, Bian Y, Yang N, Lu T, Zhu J, Tang W, Chen Y.
    Eur J Med Chem; 2022 Jan 05; 227():113953. PubMed ID: 34731760
    [Abstract] [Full Text] [Related]

  • 5. PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer.
    Kim KJ, Kim JW, Sung JH, Suh KJ, Lee JY, Kim SH, Lee JO, Kim JW, Kim YJ, Kim JH, Bang SM, Lee JS, Kim HK, Lee KW.
    Sci Rep; 2020 Jul 23; 10(1):12308. PubMed ID: 32704014
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synergistic apoptotic effects of silibinin in enhancing paclitaxel toxicity in human gastric cancer cell lines.
    Zhang Y, Ge Y, Ping X, Yu M, Lou D, Shi W.
    Mol Med Rep; 2018 Aug 23; 18(2):1835-1841. PubMed ID: 29901126
    [Abstract] [Full Text] [Related]

  • 10. Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151, and IBET-762 in OSCC cells.
    Baldan F, Allegri L, Lazarevic M, Catia M, Milosevic M, Damante G, Milasin J.
    J Oral Pathol Med; 2019 Mar 23; 48(3):214-221. PubMed ID: 30618144
    [Abstract] [Full Text] [Related]

  • 11. Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-κB Activation.
    Pan Y, Lin S, Xing R, Zhu M, Lin B, Cui J, Li W, Gao J, Shen L, Zhao Y, Guo M, Wang JM, Huang J, Lu Y.
    Antioxid Redox Signal; 2016 May 20; 24(15):839-54. PubMed ID: 26801633
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.
    Lee J, Mashima T, Kawata N, Yamamoto N, Morino S, Inaba S, Nakamura A, Kumagai K, Wakatsuki T, Takeuchi K, Yamaguchi K, Seimiya H.
    Cancer Res Commun; 2024 May 20; 4(5):1307-1320. PubMed ID: 38669046
    [Abstract] [Full Text] [Related]

  • 16. TEAD4 modulated LncRNA MNX1-AS1 contributes to gastric cancer progression partly through suppressing BTG2 and activating BCL2.
    Shuai Y, Ma Z, Liu W, Yu T, Yan C, Jiang H, Tian S, Xu T, Shu Y.
    Mol Cancer; 2020 Jan 10; 19(1):6. PubMed ID: 31924214
    [Abstract] [Full Text] [Related]

  • 17. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X, Shao S, Zhang Y, Luo A, Zhao L, Zhang L, Gu S, Zhao X.
    Exp Cell Res; 2020 Jul 15; 392(2):112034. PubMed ID: 32339606
    [Abstract] [Full Text] [Related]

  • 18. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A, Shafarin J, Unnikannan H, Al-Jabi N, Jabal RA, Bajbouj K, Muhammad JS, Hamad M.
    Int J Biol Sci; 2021 Jul 15; 17(15):4474-4492. PubMed ID: 34803511
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.